Andy Göbel

Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma

Abstract Background Anaplastic ependymoma is a rare and aggressive central nervous system malignancy for which effective systemic treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate targeting human epidermal growth factor receptor 2 (HER2), h...